Mindset Pharma Inc. (CSE: MSET | FSE: 9DF | OTCQB: MSSTF), a drug discovery and development company focused on creating novel, optimized, next-generation psychedelic and non-psychedelic medications to treat neuropsychiatric and neurological disorders with unmet medical needs, today announced the filing of 16 different national applications for the protection of one of four of the Company’s key Families of novel, next-generation psychedelics with differentiated characteristics.
Included within these applications are several drug candidates that the Company classifies as belonging to “Family 1”, which are described as second-generation psilocybin analogs, with potential improvements in effect size, safety, safety, and manufacturing compared to psilocin and psilocybin. Mindset’s Family 1 scaffold includes the first elected Mindset clinical candidate, MSP-1014, which is the Company’s most advanced drug candidate, a psilocybin-like chemical entity that has the potential to be a best-in class psychedelic treatment, and more effective alternative. MSP-1014 has demonstrated improved efficacy, with reduced potential side effects, and safety profile compared to the first-generation drug candidate, psilocybin, in preclinical studies. Mindset filed national applications in 16 different countries altogether, including the principal South East Asian markets.
“With Mindset’s goal of disrupting existing treatment paradigms to improve patient outcomes, filing multiple international applications for Family 1 will offer protection for our drug candidates especially as we look to move MSP-1014 into human clinical trials as early as 2023.” “Mindset is applying state of the art innovative medicinal chemistry to expand our rich pipeline of optimized psychedelic medications with improved overall efficacy and reduced toxicity profiles and we will continue to protect our compound pipeline and ensure that we provide the most effective options for patients with neurological and psychiatric disorders.”
James Lanthier, CEO
In order to further broaden its intellectual property portfolio, Mindset has also recently filed another provisional application with the USPTO applying a new elegant chemical structural strategy to Family 1, which has never been explored before, to enhance its overall intellectual property moat around Family 1 candidates.
The Company is pleased to announce that it has granted options to purchase an aggregate of 200,000 common shares of the Company exercisable at a price of $0.55 per share and expiring on September 6, 2023, to an investor relations consultant of the Company.
About Mindset Pharma Inc.
Mindset Pharma Inc. is a drug discovery and development company focused on creating optimized and patentable next-generation psychedelic medicines to treat neurological and psychiatric disorders with unmet needs. Mindset was established in order to develop next-generation pharmaceutical assets that leverage the breakthrough therapeutic potential of psychedelic drugs. Mindset is developing several novel families of next-generation psychedelic compounds, as well as an innovative process to chemically synthesize psilocybin in addition to its own proprietary compounds. The company has a co-development agreement with the McQuade Center for Strategic Research and Development, a member of the Otsuka Pharmaceuticals family of companies, for its short-duration compounds, Mindset Families 2 & 4.